Gilead Sciences Allocates $200 Million to Settle HIV Drug Investigation

Gilead Sciences has set aside $200 million to potentially resolve an ongoing investigation into its promotional speakers program related to HIV drugs. This announcement, made in a securities filing, indicates the company’s proactive approach to address concerns raised by federal prosecutors in Manhattan.

The investigation began when Gilead received a subpoena in 2017, and the company first disclosed the inquiry in 2018. In a statement, Gilead confirmed it has taken a litigation accrual for a possible settlement, reflecting its commitment to compliance amid scrutiny over how pharmaceutical companies promote their products.

Promotional speaker programs, where healthcare professionals are compensated to discuss drugs, have faced significant regulatory oversight. Notably, in 2020, Swiss firm Novartis paid over $600 million to settle similar allegations regarding its speaker program, which was deemed a vehicle for bribing doctors to prescribe its medications.

Despite these challenges, Gilead reported a 16% increase in HIV drug sales, totaling $5.45 billion in the fourth quarter of 2024, contributing to a rise in its stock price. The company is also preparing to launch a new drug, lenacapavir, designed to protect against HIV infection later this year.

As Gilead navigates these legal complexities, the industry will be watching closely to see how this situation unfolds and what it means for future regulatory practices in pharmaceutical marketing.